Joan S. Brugge

Harvard University — United States

Medicine · Health Sciences

126h-index55.2kcitations596works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(98), HER2/EGFR in Cancer Research(74), Cancer Cells and Metastasis(68), Cell Adhesion Molecules Research(57), Virus-based gene therapy research(44)

Publications596 total

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Methods 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Abstract B004: Phase 1b trial of BCL-XL degrader DT2216 and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
Molecular Cancer Therapeutics·2025
Defining breast epithelial cell types in the single-cell era
Developmental Cell·2025· 4 citedOpen Access
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer
Gynecologic Oncology·2025· 2 cited
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X <sub>L</sub> degradation to overcome cancer chemoresistance
2025· 7 citedOpen Access
Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy
2025· 1 citedOpen Access
Abstract 1249: Chemotherapy enriches one of two pre-existing coordinated cellular programs characterized by inflammatory and stress pathways in high grade serous ovarian cancer
Cancer Research·2025
Abstract 7152: High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
Cancer Research·2025
Abstract 3821: Epigenetic mechanisms in early-onset hereditary cancer: Insights from a new Brca1 mouse model
Cancer Research·2025
Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness
npj Breast Cancer·2024· 7 citedOpen Access
Author Correction: Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer
Nature Genetics·2024· 1 citedOpen Access
page 1 of 30Next →

Frequent Co-authors

Senthil K. Muthuswamy(5), Jayanta Debnath(4), Sheila Μ. Thomas(3), Taru Muranen(3), Lewis C. Cantley(3), Hanna Y. Irie(3), Daniel A. Haber(3), Dennis C. Sgroi(3), Michael Overholtzer(3), Marcin Iwanicki(3), Sanford J. Shattil(3), Gordon B. Mills(3), Laura M. Selfors(3), Edwin Clark(2), Alexandra Grassian(2), Gerhard Wagner(2), Loling Song(2), Sizhen Gao(2), Steven J. Isakoff(2), Beth Muir(2)